SEARCH

SEARCH BY CITATION

References

  • 1
    Razquin C, Martinez JA, Martinez-Gonzalez MA, et al. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects at high cardiovascular risk. Br J Nutr 2009;102:672-679.
  • 2
    Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R. Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients. PPAR Res 2009;2009:874126.
  • 3
    Morini E, Tassi V, Capponi D, et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity (Silver Spring) 2008;16:1467-1470.
  • 4
    Razquin C, Marti A, Martinez JA. Evidences on three relevant obesogenes: MC4R, FTO and PPARgamma. Approaches for personalized nutrition. Mol Nutr Food Res 2011;55:136-149.
  • 5
    Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003;40:773-780.
  • 6
    Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497.
  • 7
    Rothman K, Sander G, Timothy L. Meta-Analysis. Modern Epidemiology. (3rd ed.) Philadelphia: Lippincott Williams & Wilkins; 2008. p. 757.
  • 8
    Martinez-Gonzalez MA, Sanchez-Villegas A, De Irala J, Marti A, Martinez JA. Mediterranean diet and stroke: objectives and design of the SUN project. Seguimiento Universidad de Navarra. Nutr Neurosci 2002;5:65-73.
  • 9
    Segui-Gomez M, de la Fuente C, Vazquez Z, de Irala J, Martinez-Gonzalez MA. Cohort profile: the 'Seguimiento Universidad de Navarra' (SUN) study. Int J Epidemiol 2006;35:1417-1422.
  • 10
    Bes-Rastrollo M, Perez Valdivieso JR, Sánchez-Villegas A, Alonso A, Martinez-Gonzalez MA. Validación del peso e indice de masa corporal auto-declarados de los participantes de una cohorte de graduados universitarios. Rev Esp Obes 2005;183-189.
  • 11
    Chuang LM, Hsiung CA, Chen YD et al. Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med (Berl) 2001;79:656-664.
  • 12
    Kuliczkowska J, Filus A, Trzmiel A et al. PPAR-gamma2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw. Endokrynol Pol 2008;59:312-315.
  • 13
    Ostergard T, Ek J, Hamid Y et al. Influence of the PPAR-gamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. Horm Metab Res 2005;37:99-105.
  • 14
    Pisabarro RE, Sanguinetti C, Stoll M, Prendez D. High incidence of type 2 diabetes in peroxisome proliferator-activated receptor gamma2 Pro12Ala carriers exposed to a high chronic intake of trans fatty acids and saturated fatty acids. Diabetes Care 2004;27:2251-2252.
  • 15
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
  • 16
    Benjamini Y, Hochberg Y. Controlling the false discovert rate—a practical and powerful approach to multiple testing. J R Stat Soc Ser B-Methodol 1995;57:289-300.
  • 17
    Razquin C, Martinez JA, Martinez-Gonzalez MA et al. A Mediterranean diet rich in virgin olive oil may reverse the effects of the -174G/C IL6 gene variant on 3-year body weight change. Mol Nutr Food Res 2010;54 Suppl 1:S75-S82.
  • 18
    Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: Methodological overview. PLoS Med 2011;8:e1001026.
  • 19
    Speakman JR, Levitsky DA, Allison DB et al. Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis Model Mech 2011;4:733-745.
  • 20
    Speliotes EK, Willer CJ, Berndt SI et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-948.
  • 21
    Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002;147:495-501.
  • 22
    Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 2002;12:597-603.
  • 23
    Ben Ali S, Ben Yahia F, Sediri Y et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009;42:1642-1647.
  • 24
    Interantional HapMap Project. Available from: http://hapmap.ncbi.nlm.nih.gov/index.html.en.
  • 25
    Lindi VI, Uusitupa MI, Lindstrom J et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002;51:2581-2586.
  • 26
    Franks PW, Jablonski KA, Delahanty L et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007;50:2451-2460.
  • 27
    Adamo KB, Dent R, Langefeld CD et al. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity (Silver Spring) 2007;15:1068-1075.
  • 28
    Nicklas BJ, van Rossum EF, Berman DM et al. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001;50:2172-2176.
  • 29
    Matsuo T, Nakata Y, Katayama Y et al. PPARG genotype accounts for part of individual variation in body weight reduction in response to calorie restriction. Obesity (Silver Spring) 2009;17:1924-1931.
  • 30
    Bloss CS, Madlensky L, Schork NJ, Topol EJ. Genomic information as a behavioral health intervention: Can it work? Per Med 2011;8:659-667.